ClinicalTrials.gg
RecruitingNCT06830577Updated Jun 12, 2025

Intra-ureteric Aminophylline Instillation on Flexible Ureteroscopy Procedure

An interventional study of Usage of Aminophylline prior to ureteric dilatation in Flexible uretroscopy and Sequential teflon dilator usage prior to ureteric access sheath placement in flexible uretroscopy in Stones, Kidney and Ureteric Injury, sponsored by Ain Shams University. Recruiting at 1 site in Egypt. Open to participants aged 18 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2025-06-12.

Sponsored by Ain Shams University · Not applicable, Interventional, and Treatment

How we know

From the registry’s dates

  • Primary completion was expected by Jan 2026, 10 months ago, but the record still lists the study as recruiting.
  • Started Mar 2025; still recruiting 1 year 8 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
129
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 14 studies in Kidney Calculi by Ain Shams University — 6 open to participants now, 7 under way, none of them phase 3. Kidney Calculi · Ain Shams University.

Planned enrollment
7th of 14
129 · median 128
Started
2025
with 6 others
No phase
13 of 14
6 open now
Registered
4th of 14
by date

Among the 14 studies in Kidney Calculi by Ain Shams University, this one is the 7th largest by planned enrollment, is one of 7 that started in 2025, is one of 13 with no phase, and was the 4th registered.

Kidney Calculi

510 studies on the registry are indexed under Kidney Calculi; 147 are open to participants now.

Browse Kidney Calculi studies →

Open to participants now

6 of the 14 studies in Kidney Calculi by Ain Shams University are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 6 open studies →

Where they have run

Who these studies take

Of the 88 Kidney Calculi studies recruiting now, 48 (55%) set no upper age limit and 23 (26%) stop at 75 or younger; 6 take children under 18; 11 take healthy volunteers.

This study: 18 Years and older · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 14 studies in Kidney Calculi by Ain Shams University, or all of them as a file.
02

Study summary

in this study we are going to evaluate the efficacy of intra-ureteric aminophylline instillation in facilitating ureteric access sheath placement prior to flexible ureteroscopy in reducing ureteric injury rates.

Read the detailed description

Urolithiasis (kidney and ureteral stones) is a common urologic condition with increasing prevalence. Flexible ureteroscopy (FURS) is a minimally invasive technique widely used for upper ureteric and renal stones. Aminophylline, a methylxanthine derivative, has been shown to relax smooth muscles and was previously used intravesically to facilitate rigid ureteroscopy with reduced complications. This study aims to assess whether intra-ureteric aminophylline instillation improves the ease of ureteral access sheath (UAS) placement during FURS and reduces ureteric injuries.

patients will be divided into 3 groups:

  1. Group A (Aminophylline Group): Intra-ureteric instillation of aminophylline
  2. Group B (Ureteral Dilator Group): Traditional ureteral dilators
  3. Group C (Combination Group): Aminophylline instillation + Ureteral dilators follow up of the patients will be through the success rate or failure of ureteric access sheath placement, operative time, bleeding, intra/postoperative complications and stone clearance (3-week follow-up with CT scan)
03

Conditions studied

  • Stones, Kidney
  • Ureteric Injury

Browse trials for

Keywords

  • Aminophylline
  • Ureteric access sheath
  • ureteric injury
  • Flexible Uretroscopy
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Upper ureteric stones or renal stones \< 2 cm

Exclusion criteria

Exclusion Criteria:

  1. Ureteric strictures.
  2. anatomic renal disorders
  3. functional renal disorders
  4. Urinary tract infection.
  5. Coagulopathy and uncorrected bleeding disorders.
  6. Prior DJ stenting
  7. any for aminophylline use: ( to theophylline, ethylenediamine, or any component of the drug formulation, pregnancy or lactation, active peptic ulcer, presence of cardiologic diseases, presence of neurologic diseases, presence of renal impairment and presence of hepatic dysfunction)
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
129 participants (estimated)

Study arms

  • Experimental
    Group A: Aminophylline Group: Intra-ureteric instillation of aminophylline

    a ureteric catheter 6 Fr will be used for instillation of normal saline supplemented with aminophylline 250 mg/10 mL at three points (Pelvi-ureteric junction, upper sacroiliac joint level and proximal to uretero-vesical junction by 5 cm) then wait for 5 minutes

    Drug: Usage of Aminophylline prior to ureteric dilatation in Flexible uretroscopy

  • Active comparator
    Group B: Ureteral Dilator Group: Traditional ureteral dilators

    traditional ureteral dilators will be used. We will start by ureteral dilator 6 fr and gradually increase the size up to 12 Fr

    Device: Sequential teflon dilator usage prior to ureteric access sheath placement in flexible uretroscopy

  • Other
    Group C: Combination Group: Aminophylline instillation and Ureteral dilators

    Aminophylline will be instilled as in group (A) then followed by traditional ureteral dilatation as in group (B)

    Drug: Usage of Aminophylline prior to ureteric dilatation in Flexible uretroscopy · Device: Sequential teflon dilator usage prior to ureteric access sheath placement in flexible uretroscopy · Other: Aminophylline instillation and Ureteral dilators together

Interventions

  • DrugUsage of Aminophylline prior to ureteric dilatation in Flexible uretroscopy

    Intraureteric aminophylline installation prior to ureteric dilatation

    Also known as: Intraureteric Aminophylline instillation prior to access sheath insertion

  • DeviceSequential teflon dilator usage prior to ureteric access sheath placement in flexible uretroscopy

    traditional ureteral dilators will be used. We will start by ureteral dilator 6 fr and gradually increase the size up to 12 Fr

    Also known as: ureteric teflon dilators prior to access sheath insertion

  • OtherAminophylline instillation and Ureteral dilators together

    Aminophylline will be instilled as in group (A) then followed by traditional ureteral dilatation as in group (B) prior to placing the ureteric access sheath

    Also known as: combination of aminophylline instillation and ureteric teflon dilators prior to access sheath insertion

06

What researchers measure

Primary outcomes

  1. The successful placement of ureteric access sheath

    we will assess the successful placement of ureteric access sheath in patients (that the access sheath is passed on the guide wire till the pelviureteric junction portion of the ureter after the usage of intraureteric aminophylline or teflon dilators or the usage of both.

    Time frame: intraoperative application of the access sheath

Secondary outcomes

  1. successful stone clearance

    the stone free rate following intervention

    Time frame: 3 weeks postoperative follow up with urinary tract multislice CT

07

Study locations

1 of 1 sites recruiting
  • Ain Shams University Hospitals
    CAiro, Abassia 11517, Egypt
    Recruiting
    • Ali Khaled Mohammed Ali M. Dr. Ali Khaled, MSc. · Contactali.khaled94@gmail.com · 201099978174
    • Younan R. Lecturer Dr. Younan Ramsis Samir, PhD. · Contact201255511
    • Younan R. Samir, PhD. · Principal investigator
    • Mahmoud A. Dr. Mahmoud Ahmed, PhD. · Principal investigator
08

References and documents

Publications

  • Shabayek M, Osman T, Wahb M, Elmoazen M, Osman D, Saafan A. Intravesical aminophylline instillation as an alternative for balloon dilatation prior to semi-rigid ureteroscopic management of distal ureteral stones. World J Urol. 2022 Jul;40(7):1805-1811. doi: 10.1007/s00345-022-04039-7. Epub 2022 May 26. PubMed 35618855 ↗

Individual participant data

Plan to share: No

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Mar 2025 (actual). Primary completion is estimated for Jan 2026, 10 months after the start.

Of 183 non-industry interventional studies with no phase under Kidney Calculi, half reached primary completion within 31 months of starting (the median), counting those still running; a quarter within 13 and three quarters within 54. This study's planned 10 months is below that.

Counting every sponsor, half of 199 studies reached it within 26 months; a quarter within 12 and three quarters within 51.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 3, 2025
First posted
Feb 17, 2025
StartActual
Mar 1, 2025
Primary completionEst.
Jan 1, 2026
CompletionEst.
Feb 1, 2026
Last update
Jun 12, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 12, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06830577
Responsible party
Younan Ramsis (Lecturer of Urology, Ain Shams University) — Principal investigator
First posted
Feb 17, 2025
Start date
Mar 1, 2025
Primary completion
Jan 1, 2026 (estimated)
Completion
Feb 1, 2026 (estimated)
Last update
Jun 12, 2025

Study contacts

Ali Khaled Mohammed Ali Dr. Ali Khaled, MSc.
Contact
ali.khaled94@gmail.com
+201099978174
Younan Samir, PhD
Contact
dr_yona@live.com
+201201255511
Younan Samir, PhD
principal investigator · Ain Shams University

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion